Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

MJS.V, AFFX, AFFY, ATRM, PWRM - Market Update From DrStockPick.com!

drstock-2-3

signup3m

http://pennyomega.com/img/mjs.jpg

Majestic Gold Corp. (TSX.V:MJS) (FSE:MJT) is pleased to announce the results of an updated resource estimate on its Song Jiagou Mine.

As part of the ongoing assessment on the Song Jiagou Mine, Wardrop Engineering Inc. ("Wardrop") has revised their previous resource estimate (NR 23 April, 2010) as a result of the revision to the contract mining costs (NR 30 September 2010) which allowed cut-off grades to be reduced from 0.40 g/t to 0.30 g/t and warranted a revision of the block model.

Subsequent to the initial resource estimate, Wardrop determined that rotating the block model perpendicular to drilling direction was the most favorable orientation to evaluate the deposit and to calculate the revised resource. The new cut-off grade and the re-orientation of the model significantly increased the overall size of the resource and the contained ounces of gold in both the inferred and indicated categories.

The revised resource is:

-----------------------------------------------------------------
Grade Au
Category Tonnes(i) (g/t)(ii) Contained oz Au
-----------------------------------------------------------------
Indicated 33,739,586 1.147 1,244,211
-----------------------------------------------------------------
Inferred 38,812,054 1.467 1,830,576
-----------------------------------------------------------------
(i)Calculations conducted using 0.30 g/t cut-off
(ii)Gold grades were capped at 40 g/t

The most significant changes from the previous estimate are:

-- Increase in Indicated tonnes by 35.34% to 33,739,586 tonnes
-- Increase in Indicated contained gold by 24.09% to 1,244,211 ounces
-- Increase in Inferred tonnes by 37.96% to 38,812,054 tonnes
-- Increase in Inferred contained gold by 7.48% to 1,830,576 ounces

The increase in the size of the resource from 53 to 72.5 million tonnes will very significantly reduce the strip ratios to be used as Majestic continues its engineering studies on the Song Jiagou mine. Wardrop will move forward now to re-evaluate a production pit design.

For More Information On Majestic Gold: www.majesticgold.net

******************************************

power3

Power3 Medical Products, Inc. (OTC.BB:PWRM) recently delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.

Power3 has filed several patent applications for its NuroPro® technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS diseases, for which it is currently engaged in Phase II clinical trials.

******************************************

Aetrium Inc. (Nasdaq:ATRM) announced that Joseph C. Levesque, its long time chief executive officer, will retire from that post effective December 31, 2010. John J. Pollock, the company’s president and chief operating officer, will become the company’s chief executive officer upon Mr. Levesque’s retirement. Mr. Levesque will continue as the chair of the company’s board of directors. Mr. Pollock, 51, has served in a variety of management positions with the company since 1996. He has served as the company’s president since October 2009 and as the company’s chief operating officer since August 2010. From December 2001 to October 2009, Mr. Pollock served as the vice president and general manager of the company’s North St. Paul operations.

Aetrium Incorporated, together with its subsidiaries, designs, manufactures, and markets electromechanical equipment used by the semiconductor industry to handle and test integrated circuits (ICs).

******************************************

Affymax, Inc. (Nasdaq:AFFY) announced that following pre-New Drug Application (NDA) discussions with the U.S. Food and Drug Administration (FDA), the companies will move forward with their regulatory strategy for the investigational drug, peginesatide, for the treatment of anemia in chronic renal failure (NYSEMKT:CRF) patients on dialysis in the United States. “Our plan is to pursue approval of peginesatide for the treatment of anemia in CRF patients on dialysis,” said Arlene M. Morris, chief executive officer of Affymax. “Based on our meeting with FDA, we believe the data from our completed trials are sufficient for review of our NDA for this indication.

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions.

******************************************

Affymetrix Inc. (Nasdaq:AFFX) announced that it will webcast the Company’s previous presentation at the 22nd Annual Piper Jaffray Health Care Conference on Wednesday, December 1, 2010, at 1:30 p.m. EST. Archived webcasts will be available for 30 days.

Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 22,000 peer-reviewed papers have been published using the technology.

****************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty-five thousand dollars in cash from Majestic Gold Corp. (TSX Venture Exchange (TSX.V:MJS) and the Frankfurt Stock Exchange (FSE:MJT)) for 30 (thirty) days of advertising, as well as for assistance in becoming a fully reporting publicly trading Bulletin Board company.

Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).

drstbc